|
|
|
|
Дата |
|---|
| 01.09.2026 |
| 31.08.2026 |
| 28.08.2026 |
| 27.08.2026 |
| 26.08.2026 |
| 25.08.2026 |
| 24.08.2026 |
| 21.08.2026 |
| 20.08.2026 |
| 19.08.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
9.10
|
11.09
|
9.51
|
9.43
|
9.895
|
9.895
|
|
|
12 032.61
|
55.00
|
|
9.10
|
11.00
|
9.84
|
9.55
|
9.84
|
9.60
|
|
|
38 354.89
|
166.00
|
|
9.10
|
11.09
|
10.29
|
9.60
|
10.29
|
9.825
|
|
|
68 079.64
|
193.00
|
|
9.02
|
10.38
|
9.55
|
9.55
|
10.23
|
10.205
|
|
|
34 184.74
|
139.00
|
|
9.04
|
9.62
|
9.89
|
9.51
|
9.94
|
9.63
|
|
|
65 093.78
|
203.00
|
|
9.05
|
10.58
|
9.68
|
9.68
|
9.98
|
9.73
|
|
|
17 795.20
|
60.00
|
|
8.96
|
10.58
|
9.36
|
9.07
|
9.87
|
9.685
|
|
|
91 292.22
|
255.00
|
|
8.98
|
11.00
|
9.77
|
9.49
|
9.77
|
9.49
|
|
|
21 900.99
|
45.00
|
|
9.42
|
9.98
|
9.82
|
9.54
|
10.03
|
9.54
|
|
|
38 869.88
|
80.00
|
|
9.42
|
9.96
|
10.05
|
9.76
|
10.05
|
9.86
|
|
|
9 698.65
|
39.00
|
Turn Therapeutics Inc. is a pharmaceutical and medical device development company built around a proprietary platform of technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis.
GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.
Показать все Скрыть